#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Efficacy and Safety of Ultrahypofractionated Proton Therapy in the Treatment of Prostate Cancer in Real-World Czech Practice

A team from the Prague Proton Therapy Center, led by Associate Professor Jiří Kubeš, published a study with nearly 300 patients in the prestigious International Journal of Radiation Oncology, Biology, Physics. It demonstrates the significant efficacy and low toxicity of the ultrahypofractionated proton therapy regimen in patients with prostate cancer. We summarize the main results.
Source: Proton Radiotherapy 5. 4. 2023

News Dynamics of Allergy Development in Children

The prevalence of allergic diseases in children in developed countries has been steadily increasing in recent decades. Slovak authors attempted to describe the dynamics of the development of allergic symptoms in a prospective cohort of children who developed atopic dermatitis, rhinoconjunctivitis, wheezing, urticaria, or food allergy within the first 5 years of life.
Source: Allergic Reactions 1. 10. 2020

News From Hell to the Light at the End of the Tunnel – A Task for Eletriptan

In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?
Source: Treatment of Severe Migraine 4. 1. 2022

News FLEX – A New Predictive Model for Assessing Follicular Lymphoma Risks

Overall survival of patients with advanced-stage follicular lymphoma (FL) who experience early disease progression after chemotherapy remains low. Currently used clinical prognostic models do not provide optimal sensitivity and specificity for identifying this patient subgroup. The presented study by an international team of authors introduced a new assessment index that achieves better outcomes.
Source: Non-Hodgkin Lymphomas and CLL 14. 11. 2020

News What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?

Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD). What is the efficacy and safety of sorafenib in this patient population, and does it differ from patients with liver cancers caused by viral infection or alcohol abuse? This intrigued a team of researchers from Melbourne, Australia.
Source: Oncological Treatment 31. 10. 2022

Journal articles Gynecologic robotic surgery and our initial experience

Author of the article: R. Pilka, P. Dzvinčuk Source: Česká gynekologie | 6/2010 20. 12. 2010

News Traveling with MS – Is Vaccination a Limitation?

What about the need for vaccination when traveling abroad? Which vaccines should you be cautious about? And how to time vaccination concerning disease activity and the individual medications used in multiple sclerosis (MS) therapy?
Source: Multiple Sclerosis 5. 6. 2023

News Expanded Hemodialysis as an Alternative to Hemodiafiltration

Expanded hemodialysis is a new type of therapy that effectively removes middle molecules from the blood of dialysis patients. The aim of the Spanish authors was to compare its efficiency with hemodiafiltration in terms of clearance of middle molecules in an open randomized clinical study.
Source: Chronic Kidney Disease 9. 12. 2021

News Spectrum of Mechanisms of Action of Fenfluramine in the Treatment of Rare Epilepsies

Fenfluramine (FFA) is an anticonvulsant used in the treatment of rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. In addition to effectively reducing seizure frequency, it also mitigates non-seizure comorbidities in patients with these conditions. Last year, Belgian authors published a detailed review of all its described mechanisms of action. They also explain how these mechanisms might contribute to the clinical benefits of FFA beyond seizure suppression, such as reducing the risk of sudden unexpected death in epilepsy (SUDEP) or improving executive functions.
Source: Rare Diseases in Neurology 21. 6. 2024

News Trazodone with Extended Release Improves Patient Compliance

Since 2015, the antidepressant trazodone is available in the Czech Republic in a controlled-release formulation. A sufficiently high plasma level for 24 hours without fluctuation allows for administration only once a day, while eliminating side effects.
Source: Depression and Anxiety 20. 5. 2020

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.
Source: Oncological Treatment 22. 11. 2021

News Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS − What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?

Current treatment options for irritable bowel syndrome (IBS − irritable bowel syndrome) are relatively limited. This increases interest in complementary and alternative therapy options with plant preparations. One modality used to alleviate IBS symptoms is Aloe barbadensis Mill. The aim of a clinical study by Swedish researchers was to assess the effect of aloe on IBS symptoms compared to a control treatment with inulin.
Source: Irritable Bowel Syndrome 12. 11. 2022

News Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs

In the context of the significant advancements in the field of immunotherapy and evidence of its efficacy in the treatment of chronic lymphocytic leukemia, it is pertinent to ask how this will influence therapeutic strategies in the context of first-line treatment and what the role of chemoimmunotherapy will be in the algorithms for CLL. At the 2019 NCCN Annual Congress, a panel of experts, led by Professors William G. Wierda from Texas MD Anderson Cancer Center and Jennifer R. Brown from Dana-Farber Cancer Institute, debated this topic.
Source: Chronic Lymphocytic Leukemia 22. 4. 2020

News What did the first data from the pilot lung cancer screening show?

Czech pulmonologists have released the first interim results of this year's pilot testing of heavy smokers due to the risk of lung cancer. More than 4,000 patients passed through the hands of general practitioners, and 900 subsequently underwent low-dose CT examination. What other specific findings emerge from the data collection? And what challenges do the experts involved in this program face?
Source: MDT Board 5. 12. 2022

News Can Ketogenic Diet or Intermittent Fasting Help Patients with DM2 in Controlling Weight and Glycemia?

The foundation of managing type 2 diabetes mellitus (DM2) typically involves lifestyle adjustments, including dietary changes. Can intermittent fasting (IF) or the ketogenic diet (KD), popular dietary trends, help diabetics with weight loss and reduction of glycated hemoglobin (HbA1c) levels? The answer was sought by authors of a systematic review and meta-analysis comparing IF or KD with other dietary regimes.
Source: Modern Treatment of Diabetes 30. 5. 2023

News Chemoimmunotherapy in the Treatment of Breast Cancer − Final Results of the IMpassion130 Study

According to international recommendations, treatment with the immune checkpoint inhibitor atezolizumab in combination with the cytostatic nab-paclitaxel is used for patients with locally advanced or metastatic breast cancer where PD-L1 protein expression is detected on the surface of tumor-infiltrating immune cells (IC). The final results regarding overall survival and long-term safety of this treatment in patients who participated in the registration study IMpassion130 were presented at this year's European Society for Medical Oncology (ESMO) congress, which was held virtually due to circumstances.
Source: Breast Carcinoma 25. 10. 2020

News Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker

The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of prostate-specific antigen (PSA), free PSA (fPSA), and the isoform [-2]proPSA (p2PSA). Its use in prostate cancer diagnostics can reduce the number of unnecessary prostate biopsies compared to determining PSA alone. A recently published Czech study assessed the utility of PHI in evaluating the aggressiveness of prostate cancer. The study compared PHI values with the results of preoperative biopsy and postoperative prostate histology in men indicated for radical prostatectomy.
Source: Prostate Health Index 2. 2. 2020

News Subclinical Hypothyroidism Associated with the Use of Allopurinol? What the Results of a Large Multicenter Study Suggested

Allopurinol is a widely used drug for the treatment of hyperuricemia and gout. The retrospective study presented below investigated whether its long-term use is associated with an increased risk of developing subclinical hypothyroidism.
Source: Thyroid Disorders 18. 11. 2021

Journal articles Prospects for the treatment of osteoarthritis

Author of the article: K. Pavelka Source: Česká revmatologie | 1/2015 5. 3. 2015

News Probiotics as a Helper in the Fight Against Pregnancy Gingivitis

Gingivitis is a common problem during pregnancy. In addition to quality oral hygiene, regular consumption of probiotic preparations containing certain strains of Limosilactobacillus reuteri can also help reduce or completely eliminate it.
Source: GI, colic and microbiome 2. 9. 2022

News Chairwoman of Revma Liga ČR: I Hope We Improve Our Approach and Treatment of Osteoporosis in the Czech Republic

Patients with inflammatory rheumatic diseases have a significantly increased risk of developing osteoporosis and related fractures. At the same time, this disease is considerably underestimated in the Czech Republic, and more attention is given to it only at the stage of osteoporotic fractures. To what extent does the patient organization Revma Liga ČR, which unites patients with rheumatic diseases, engage in this issue? We asked its chairwoman Edita Müllerová.
Source: Osteoporosis – Trends in Sequential Therapy 20. 12. 2023

News Efficacy and Safety of Romosozumab in Postmenopausal Women with Osteoporosis and Renal Impairment

The coexistence of osteoporosis and chronic kidney disease (CKD) increases the risk of fractures and overall mortality in patients. A recent post-hoc analysis of two controlled randomized multicenter studies (FRAME and ARCH) investigated the efficacy and safety of romosozumab in postmenopausal women with osteoporosis and mild to moderate CKD.
Source: Osteoporosis – Trends in Sequential Therapy 9. 5. 2024

News Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture

Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented below examined the risk of subsequent fractures in postmenopausal women after an initial fracture depending on its location.
Source: Osteoporosis – Trends in Sequential Therapy 4. 9. 2023

News Hydrotherapy in the Treatment of Non-Healing Wounds

For the treatment of wounds, it is crucial how they are managed during the cleaning and granulation phases. For most non-healing wounds, so-called Hydrotherapy (treatment with hydroresponsive dressings) is suitable, which involves just two steps. The essence of Hydrotherapy is the maintenance of a moist environment and, if possible, a constant temperature in the wound.
Source: Wound Healing 10. 2. 2021

News Impact of Combined Oral Contraceptives on Body Weight

A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and 2 mg chlormadinone acetate (CMA) for 6 months, comparing the results between the two groups.
Source: Oral Contraception 10. 4. 2022

1 33 34 35 36 37 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#